Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB3 over exp||prostate cancer||predicted - sensitive||Patritumab||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Patritumab (U3-1287) treatment decreased viability of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture but did not inhibit tumor growth in a patient-derived xenograft (PDX) model, and did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775).||34753775|